Human infection with *Strongyloides stercoralis* and other related Strongyloides species

THOMAS B. NUTMAN*

Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 4 – Room B1-03, 4 Center Dr., Bethesda, MD 20892-0425, USA

SUMMARY

The majority of the 30–100 million people infected with *Strongyloides stercoralis*, a soil transmitted intestinal nematode, have subclinical (or asymptomatic) infections. These infections are commonly chronic and longstanding because of the autoinfective process associated with its unique life cycle. A change in immune status can increase parasite numbers, leading to hyperinfection syndrome, dissemination, and death if unrecognized. Corticosteroid use and HTLV-1 infection are most commonly associated with the hyperinfection syndrome. *Strongyloides* adult parasites reside in the small intestine and induce immune responses both local and systemic that remain poorly characterized. Definitive diagnosis of *S. stercoralis* infection is based on stool examinations for larvae, but newer diagnostics – including new immunoassays and molecular tests – will assume primacy in the next few years. Although good treatment options exist for infection and control of this infection might be possible, *S. stercoralis* remains largely neglected.

Key words: Strongyloidiasis, *Strongyloides stercoralis*, autoinfection, hyperinfection, anthelmintic therapy, corticosteroids.

INTRODUCTION

Strongyloidiasis, the disease caused by the infection with *Strongyloides stercoralis*, and to a lesser extent by *Strongyloides fuelleborni fuelleborni* and *S. fuelleborni kelleyi*, is a soil-transmitted helminthiasis with an estimated 30–100 million people infected worldwide (Genta, 1989; Schar *et al.* 2013). Although the burden of the disease has been felt to be underestimated (Viney and Lok, 2007; Olsen *et al.* 2009; Schar *et al.* 2015, 2014), *S. stercoralis* infections in humans range from asymptomatic light infections to chronic symptomatic strongyloidiasis. However, uncontrolled multiplication of the parasite (hyperinfection) and potentially life-threatening dissemination of larvae in immunocompromised patients result in mortality rates of up to 85% (Keiser and Nutman, 2004; Mejia and Nutman, 2012).

The parasite, occurring naturally in dogs, primates and humans, is endemic to the tropics and subtropics; foci of infection occur in temperate regions as well (Genta, 1989; Schar *et al.* 2013) where poor sanitation or other factors facilitate the transmission through fecal contamination. In parts of Africa and in Papua New Guinea, human infections caused by *S. fuelleborni fuelleborni* and

* Corresponding author: Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 4 – Room B1-03, 4 Center Dr., Bethesda, MD 20892-0425, USA. Tel: 301-496-5399. Fax: 301-480-3757. E-mail: tnutman@niaid.nih.gov

S. fuelleborni kelleyi respectively have been reported (Pampiglione and Ricciardi, 1971; Hira and Patel, 1977; Vince *et al.* 1979; Crouch and Shield, 1982; Evans *et al.* 1991; Freedman, 1991; Ashford *et al.* 1992). In Africa, *S. fuelleborni fuelleborni* is primarily a parasite of primates, but in Papua New Guinea no animal host has been demonstrated for *S. fuelleborni kelleyi* (Ashford *et al.* 1992; Viney and Lok, 2007).

Strongyloides stercoralis is unique among nematodes infectious for humans in that larvae passing in the feces can give rise to a free-living generation of worms which, in turn, give rise to infective larvae. This so-called heterogonic development process serves as an amplification mechanism that allows for increased numbers of infective larvae in the external environment. The infective larvae are active skin penetrators; infection *per os*, while possible, is probably of limited importance. Because the parasitic female's eggs hatch often within the gastrointestinal tract, the potential for autoinfection exists when precociously developing larvae attain infectivity while still in the host. When the rate of autoinfection escapes control by the host, massive re-penetration and larval migration may result.

LIFE CYCLE

The *S. stercoralis* (and *S. fuelleborni* spp.) life cycle encompasses both free-living and parasitic stages. Adult female worms parasitizing the human small intestine lay eggs in the intestinal mucosa that hatch into rhabditiform larvae, which are shed in

the stool. In the environment, under warm moist conditions that often characterize the tropical and subtropical endemic areas, rhabditiform larvae can either moult into infective filariform larvae or develop through succeeding rhabditiform stages into free-living adults. Sexual reproduction occurs exclusively in the free-living stage.

Humans are generally infected transcutaneously, although infection has also been experimentally induced by oral administration of water contaminated with filariform larvae (Grove, 1996). After dermal penetration, the filariform larvae, through undefined mechanisms, migrate to the small intestine. The most clinically relevant, though perhaps not the predominant (Mansfield *et al*. 1996), migration is the classic pulmonary route, in which organisms enter the bloodstream and are carried to the lungs, ascending the tracheobronchial tree to enter the gastrointestinal tract. Only female adults are detectable in humans and subsequent reproduction occurs asexually through parthenogenesis (Neva, 1986).

Some rhabditiform larvae transform into invasive filariform larvae before being excreted. As such, they are capable of re-infecting the host by invading the intestinal wall or the perianal skin (Grove, 1996). This autoinfective cycle can occur at a low level throughout infection and allows subsequent generations to persist in the host indefinitely (Neva, 1986).

In the immunocompetent host, it is felt that cellular immune effector mechanisms and intrinsic parasite biology both serve to regulate the population density of adult worms in the intestine. With an alteration in host immune responsiveness, even one adult female can multiply rapidly by parthenogenesis, leading to accelerated autoinfection and/or dissemination.

EPIDEMIOLOGY

While endemic to the tropics and subtropics, foci of infection occur in temperate regions such as Japan, Italy, Australia and the USA (Genta, 1989; Al-Hasan *et al*. 2007; Schar *et al*. 2013). Immigrants and refugees comprise a significant population at risk for strongyloidiasis in high- and middle-income countries (Posey *et al*. 2007; Schar *et al*. 2013).

Prevalence and global distribution

There is little consensus about prevalence rates and the global distribution of human infections with *S. stercoralis*. There is, however, a great degree of consensus about the fact that the prevalence of strongyloidiasis has long been underestimated (Olsen *et al*. 2009; Schar *et al*. 2013; Khieu *et al*. 2014; Toledo *et al*. 2015). Although prevalence and global distribution patterns have been recently examined, aggregated detailed distribution maps and country by country data [cf. (Schar *et al*. 2013; Toledo *et al*. 2015)] are beyond the scope of this review

Transmission

While *Strongyloides* is most commonly acquired transcutaneously, high prevalence rates in institutionalized subjects raise speculation about alternate routes of transmission (Yoeli *et al*. 1972; Gatti *et al*. 2000; Robson *et al*. 2009). A Japanese study found support to this claim by observing a higher prevalence of *Strongyloides* infection in patients with *Blastocystis hominis*, a protozoan acquired by the fecal oral route (Czachor and Jonas, 2000). However, standard rather than strict contact precautions appear sufficient for prevention of nosocomial transmission based on case reports of patients with disseminated disease (Sugiyama *et al*. 2006). Transmission of *Strongyloides* infection after transplantation of kidneys, pancreatic allograft or intestines has been suggested by several reports where donors but not recipients had a history of travel to a *Strongyloides* endemic regions of the world (Ben-Youssef *et al*. 2005; Said *et al*. 2007; Patel *et al*. 2008) (see section below).

CLINICAL MANIFESTATIONS

Acute Strongyloidiasis

The clinical manifestations of acute strongyloidiasis are associated with the path of larval migration to the small intestine. Infected individuals may experience irritation at the site of skin penetration by larvae followed occasionally by localized oedema or urticaria. Within a week following infection, a dry cough and/or tracheal irritation may occur. Gastrointestinal symptoms such as diarrhoea, constipation, abdominal pain, or anorexia can occur (Keiser and Nutman, 2004) following the establishment of the infection in the small intestine.

Chronic Strongyloidiasis

Chronic infection with *S. stercoralis* is most often clinically asymptomatic (Grove, 1989). Since up to 75% of persons may have peripheral eosinophilia or elevated IgE levels (Rossi *et al*. 1993), *Strongyloides* should be considered in the differential diagnosis of high grade and/or persistent eosinophilia in travellers or expatriates from endemic areas (O'Connell and Nutman, 2015).

Symptomatic individuals may complain of diarrhoea, constipation, intermittent vomiting or borborygmus. Dermatologic manifestations such as recurrent urticaria can occur (Leighton and MacSween, 1990) as can *larva currens* (pruritic linear streaks located along the lower trunk, thighs and buttocks) as a result of migrating larvae (Pelletier, 1984; Pelletier and Gabre-Kidan, 1985; Grove, 1996). Unusual manifestations of chronic strongyloidiasis include arthritis (Richter *et al*. 2006); nephrotic syndrome (Hsieh *et al*. 2006),

chronic malabsorption (Atul *et al*. 2005), duodenal obstruction (Harish *et al*. 2005; Suvarna *et al*. 2005), focal hepatic lesions (Gulbas *et al*. 2004) and recurrent asthma (Tullis, 1970; Dunlap *et al*. 1984).

Hyperinfection syndrome/disseminated infections

Hyperinfection describes the syndrome of accelerated autoinfection, generally – although not always (Husni *et al*. 1996; Tiwari *et al*. 2012; Dogan *et al*. 2014) – the result of an alteration in immune status. The distinction between autoinfection and hyperinfection is quantitative and not strictly defined. Therefore, hyperinfection syndrome implies the presence of signs and symptoms attributable to increased larval migration. Development or exacerbation of gastrointestinal and pulmonary symptoms is seen, and the detection of increased numbers of larvae in stool and/or sputum is the hallmark of hyperinfection. Larvae in non-disseminated hyperinfection are increased in numbers but confined to the organs normally involved in the pulmonary autoinfective cycle (i.e. gastrointestinal tract, peritoneum and lungs), although enteric bacteria, that can be carried by the filariform larvae or gain systemic access through intestinal ulcers, may affect any organ system.

The term disseminated infection is often used to refer to migration of larvae to organs beyond the range of the pulmonary autoinfective cycle. This does not necessarily imply a greater severity of disease. Extra-pulmonary migration of larvae has been shown to occur routinely during the course of chronic *S. stercoralis* infections in experimental dogs (Schad *et al*. 1989) and has been reported to cause symptoms in humans without other manifestations of hyperinfection syndrome (Lai *et al*. 2002). Similarly, many cases of hyperinfection are fatal without larvae being detected outside the pulmonary autoinfective route.

General features

The clinical manifestations of *S. stercoralis* hyperinfection vary widely. The onset may be acute (Thomas and Costello, 1998) or insidious (Wurtz *et al*. 1994). Fever and chills are not uniformly present and should prompt a search for an associated bacterial infection. Other constitutional symptoms include fatigue (Liepman, 1975), weakness (Chu *et al*. 1990) and total body pain (Chaudhuri *et al*. 1980). Blood counts performed during hyperinfection may show eosinophilia but more often show a suppressed eosinophil count (Grove, 1996). Patients who have increased peripheral eosinophilia during hyperinfection appear to have a better prognosis (Jamil and Hilton, 1992).

Gastrointestinal manifestations

Gastrointestinal symptoms are common but are non-specific. Some case reports do not mention any gastrointestinal symptoms (Liepman, 1975). Abdominal pain (Celedon *et al*. 1994), often described as crampy or bloating in nature, watery diarrhoea, constipation anorexia, weight loss (Scowden *et al*. 1978), difficulty swallowing (Yee *et al*. 1987), sore throat, nausea (Liepman, 1975), vomiting and gastrointestinal bleeding, and small bowel obstruction (Newton *et al*. 1992; Thomas and Costello, 1998) may result, with diffuse abdominal tenderness and hypoactive bowel sounds. Protein-losing enteropathy may give rise to acute or worsening hypoalbuminaemia with peripheral oedema (Ho *et al*. 1997; Yoshida *et al*. 2006) or ascites (Liepman, 1975). Hypokalaemia (Jain *et al*. 1994) or other electrolyte abnormalities may reflect these gastrointestinal disturbances. Direct stool exam usually shows numerous rhabditiform and filariform larvae. Occasionally, adult worms (Ho *et al*. 1997) and eggs (Armignacco *et al*. 1989; Cahill and Shevchuk, 1996) are also seen. Occult or gross blood is a common finding. Esophagitis and gastritis are reported, in addition to duodenitis, jejunitis, ileitis, colitis, including pseudomembranous colitis and proctitis. Mucosal ulceration is most common in the small intestine, but can occur at any level from the oesophagus (Levi *et al*. 1997) and stomach (Wurtz *et al*. 1994) to the rectum. Larvae may be seen in these ulcers on biopsy (Gompels *et al*. 1991; Wurtz *et al*. 1994; Ho *et al*. 1997). Crypts are often distorted by the numerous larvae (Wurtz *et al*. 1994) Inflammatory infiltrates (Mori *et al*. 1998) or areas of necrosis (Neefe *et al*. 1973; Yee *et al*. 1987) in involved intestinal mucosa may be present (Newton *et al*. 1992). The appendix may also be invaded by larvae (Scowden *et al*. 1978; Kramer *et al*. 1990). Abdominal imaging may show small bowel distension with air-fluid levels (Newton *et al*. 1992; Celedon *et al*. 1994). Mucosal oedema (Neefe *et al*. 1973; Mori *et al*. 1998) and findings consistent with protein-losing enteropathy may also be demonstrated radiographically. Computed tomography scans can occasionally reveal intra-abdominal lymphadenopathy (Thomas and Costello, 1998).

Cardiopulmonary manifestations

Cardiopulmonary manifestations range from none at all to cough (Nomura and Rekrut, 1996), wheezing (Kramer *et al*. 1990), (Yee *et al*. 1987), a choking sensation (Cahill and Shevchuk, 1996), hoarseness (Yee *et al*. 1987), chest pain (Chaudhuri *et al*. 1980; Cahill and Shevchuk, 1996), haemoptysis, palpitations, atrial fibrillation (Gordon *et al*. 1994), dyspnoea (Nomura and Rekrut, 1996), and, rarely, respiratory collapse. Respiratory alkalosis is common (Thompson and Berger, 1991). Pneumothorax is rarely seen (McNeely *et al*. 1980). Sputum may demonstrate filariform or rhabditiform larvae and even,

occasionally, eggs (Kennedy *et al*. 1989). These findings suggest that filariform larvae develop into adults in the lungs, and a new generation of rhabditiform larvae is produced locally (Cirioni *et al*. 1996). This hypothesis is supported by reports of adult parasites being expectorated post treatment (McLarnon and Ma, 1981) and autopsy studies showing adult worms in lung tissue (Cahill and Shevchuk, 1996). Chest imaging most frequently show bilateral or focal interstitial infiltrates. Lung tissues may show alveolar haemorrhage. Petechial haemorrhage or hyperaemia of the bronchial, tracheal and laryngeal mucosa has also been reported (Yee *et al*. 1987; Cahill and Shevchuk, 1996).

Dermatologic manifestations

Pruritic linear streaks of the lower trunk, thighs and buttocks (*larva currens*) frequently accompany hyperinfection (Ho *et al*. 1997). Petechial and purpuric rashes of these same areas, in which larvae have been demonstrated on skin biopsy is common (Ronan *et al*. 1989; Stewart *et al*. 2011). Skin manifestations of vasculitis (Harcourt-Webster *et al*. 1991) or of disseminated intravascular coagulation seen associated with

Gram-negative sepsis (Neefe *et al*. 1973) may, of course, also present during hyperinfection.

Central nervous system (CNS) manifestations

Meningeal signs and symptoms (Kramer *et al*. 1990) are the most common manifestation of CNS involvement in hyperinfection syndrome. Hyponatremia may accompany meningitis (Harcourt-Webster *et al*. 1991; Jain *et al*. 1994). In patients with meningitis, spinal fluid may show parameters of aseptic meningitis [i.e. pleocytosis, elevated protein, normal glucose, negative bacterial cultures (Scowden *et al*. 1978; Vishwanath *et al*. 1982)] or demonstrate characteristics of a Gram-negative bacterial infection. Larvae have been found in spinal fluid (Dutcher *et al*. 1990), meningeal vessels (Cahill and Shevchuk, 1996), dura, epidural, subdural and subarachnoid spaces (Neefe *et al*. 1973). Eosinophilic meningitis has not been reported.

Sepsis. Hyperinfection syndrome/disseminated are often complicated, and rarely preceded by infections caused by gut flora that gain access to extraintestinal sites, presumably through ulcers induced by the filariform larvae or by virtue of being carried on the surface or in the intestinal tract of larvae themselves. Organisms that have been reported to cause sepsis in such patients include Group D *Streptococci, Candida Streptococcus bovis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas, Enterococcus faecalis*, coagulase negative *staphylococci*

Table 1. Conditions associated with hyperinfection syndrome

Drugs/biologics
  Immunosuppressives
    Corticosteroids
    Azathioprine
    Cyclophosphamide
    Methotrexate
  Anti-neoplastic agents
    6-mercaptopurine
    Adriamycin
    Bleomycin
    Carmustine
    Chlorambucil
    Doxorubicin
    Daunorubicin
    Ifosfamide
    Melphalan
    Mitoxantrone
    VP16
    Vinca alkaloids
  Biologics
    Etanercept
    Infliximab
    Rituximab
    Antithymocyte globulin
    Anti-CD3 (OKT3)
    Mycophenolate mofetil
  Total body irradiation
Diseases/syndromes
  HTLV-1
  Hypogammaglobulinaemia (nephrotic syndrome and
    multiple myeloma)
  Haematologic malignancies and myelodysplastic
    syndromes
  Solid Organ Transplantation
  HSCT
  HIV/IRIS
  Malnutrition

and *Streptococcus pneumoniae*. Polymicrobial infections can also occur (Link and Orenstein, 1999).

Disseminated infections

Organs to which larvae have disseminated include skin, mesenteric lymph nodes, gallbladder, liver, diaphragm, heart, pancreas, skeletal muscle, kidneys, ovaries and brain (Keiser and Nutman, 2004) based largely on autopsy studies. Chronic inflammation or necrosis frequently surrounds the larvae, but tissue reactions are also frequently absent (Neefe *et al*. 1973; Takayanagui *et al*. 1995).

Conditions associated with hyperinfection syndrome and dissemination *(Table 1)*

Corticosteroids and other agents. Corticosteroids (most commonly prednisone and methyl-prednisilone) have a particularly strong and specific association with the development of hyperinfection syndrome and dissemination. Beyond their known

(and broad) effects on the host immune system, it has been postulated that corticosteroids have a direct effect on the *S. stercoralis* parasite (Genta, 1992; Ramanathan *et al.* 2011) though this has not been shown definitively. Other immunosuppressive therapies and underlying conditions (Table 1) may also predispose to dissemination. However, the concomitant administration of corticosteroids in most of these other conditions makes it difficult to assign a direct causal association. Hyperinfection syndrome has been described regardless of dose, duration or route of administration of corticosteroids. Even short courses (6–17 days) of corticosteroids in immunocompetent patients without underlying immunosuppressive conditions have even been associated with hyperinfection syndrome and death (Ghosh and Ghosh, 2007).

HTLV-1 Infection.   Human T-cell lymphotropic virus type 1 (HTLV-1) represents a significant risk factor for the development of hyperinfection syndrome or disseminated strongyloidiasis (Carvalho and Da Fonseca Porto, 2004) that may be related to HTLV-I driven alterations in IgE or associated Type-2 responses (Neva *et al.* 1998; Porto *et al.* 2001; Mitre *et al.* 2003; Santos *et al.* 2004). A growing body of evidence points to the synergistic relationship between HTLV-1 and *S. stercoralis*. Higher rates of *S. stercoralis* infection have been found in HTLV-1 patients (Carvalho and Da Fonseca Porto, 2004). *Strongyloides stercoralis* infection has been shown to influence the natural history of HTLV-1 infection (Marcos *et al.* 2011) and has been considered a co-factor in the development of HTLV-1-associated diseases (Gotuzzo *et al.* 2000).

HIV.   Strongyloidiasis was once considered an AIDS defining illness (Keiser and Nutman, 2004) yet there is no evidence that a low CD4 count will increase the risk of dissemination or decrease the chance of clearing an infection (Walson *et al.* 2010). Severe infection with *Strongyloides* has not been observed frequently with HIV-infected patients (Celedon *et al.* 1994). Hyperinfection syndrome is associated with the use of corticosteroids in the treatment of immune reconstitution inflammatory syndrome (IRIS) (Brown *et al.* 2006; Mascarello *et al.* 2011). Whether IRIS occurs after the initiation of antiretroviral therapy in patients with single infections with *S. stercoralis* remains unclear.

Strongyloides infection in the transplanted patient.   Solid organ transplants (Stone and Schaffner, 1990; Lichtenberger *et al.* 2009; Mokaddas *et al.* 2009) haematopoietic stem cell transplants (HSCT) and their pre-conditioning regimens and subsequent immunosuppression have been linked to dissemination of *S. stercoralis*.

Among the different types of transplants, HSCT has the highest incidence of fatal dissemination with a higher mortality than in other types of transplants (Wirk and Wingard, 2009). A unique complication of transplants is the development of graft *vs* host disease (GVHD). In HSCT the risk of GVHD is greater than for other types of transplants because of the use of allogeneic stem cells (non-ablative conditioning). Because the main therapy for acute GVHD is corticosteroids, it is at the time that steroids are given in the setting of chronic strongyloidiasis that the risk for dissemination is high (Choi and Reddy, 2014).

The geographical proximity to either North America or Europe by immigrants from Central and South America and Africa that are being transplanted are a sizeable 'at risk' population for dissemination of *S. stercoralis* (Wolfe *et al.* 2010; Guermani *et al.* 2013). Organ donors have also been shown to transmit *Strongyloides* infection with cases of solid organ transplant-associated *S. stercoralis* infections having been reported (Weiser *et al.* 2011).

Other.   Several case reports have supported an association between *S. stercoralis* infection hypogammaglobulinaemia associated with multiple myeloma and nephrotic syndrome (Seet *et al.* 2005; Hsieh *et al.* 2006; Yassin *et al.* 2010).

HUMAN IMMUNE RESPONSES AND PROTECTIVE IMMUNITY

The human immune response to *S. stercoralis* has not been studied in great detail. Most of our knowledge about immune responsiveness and protective immunity has come from animal studies [reviewed in this issue (Breloer and Abraham, 2016)]. These studies, that have as an added benefit the knowledge of exactly when the infection was initiated, have suggested a role for antibodies (of many isotypes) as well as for innate and adaptive immune responses in mediating resistance to infection (Fig. 1).

In humans, it has been shown, however, that Th2 response are essential to protect against hyperinfection (Porto *et al.* 2001; Iriemenam *et al.* 2010) and that individuals with strongyloidiasis develop *S. stercoralis*-specific antibodies of the IgM, IgG, IgA and IgE isotypes (McRury *et al.* 1986; Genta and Lillibridge, 1989; Atkins *et al.* 1997; Rodrigues *et al.* 2007).

The evolution of the antibody response in *S. stercoralis* infection has been difficult to discern given that only cross-sectional studies of infected people have been performed. Nevertheless, these studies of *S. stercoralis* infection have suggested that there is rapid induction of parasite-specific IgE, IgG1, IgG2 and IgG3 antibodies directed against crude *S. stercoralis* soluble extracts that is followed (often weeks to months later) with a rise in parasite-

Fig. 1. Immune responses in *Strongyloides stercoralis* infection as a function of time after infection initiation. The infective L3 larval parasites initiate infection at skin sites and activate a variety of different cell types such as innate lymphoid cells (ILCs), macrophages (MAC), dendritic cells (DCs), natural killer cells (NK), eosinophils (Eos) and basophils/mast cells (Baso/MC). At this relatively early phase of infection (or by the time the adult worms are established in the small intestine) the parasite induces the differentiation of a small number of effector Th1/Th17 and a relatively larger number of Th2 cells which together with IgE antibody, may lead to attrition of some of the parasites. At the time of patency (when larval production occurs) there is an expansion of Th2/Th9 CD4$^+$ cells, a further contraction of Th1/Th17 cells and the induction of alternatively activated macrophages (AAM). With the evolution of chronic longstanding infection, there is an associated expansion of IL-10- and/or TGFβ-producing regulatory T cells (Tregs) and a small contraction of Th2/Th9 cells.

specific IgG4. In that the IgE and IgG4 antibodies often are directed at a similar, but restricted, set of antigens (Genta and Lillibridge, 1989), it is the IgG4 antibodies that allow for the blocking of IgE-mediated effector responses (Genta *et al.* 1983; Barrett *et al.* 1988; Genta and Lillibridge, 1989) thereby modulating some of the Type-2-mediated inflammation.

Recent work has suggested that once *S. stercoralis* establishes patency [usually within 6–7 weeks following infection (Freedman, 1991)] that the infection drives a systemic cytokine response that is dominated by Th2-associated and anti-inflammatory cytokines (Anuradha *et al.* 2015*a*) (Fig. 1). This systemic response appears to reflect an expansion of antigen-specific Th2/Th9 cells with a concomitant contraction of Th1 and Th17 cells, the latter being dependent on IL-10 (George *et al.* 2014; Anuradha *et al.* 2016, 2015*b*). With appropriate anthelmintic therapy leading to cure of the *S. stercoralis* infection, many of these cytokine levels and T-cell perturbations return to their homeostatic state (Anuradha *et al.* 2015*a*, *b*).

Like many other systemic helminth infections (e.g. *Schistosoma mansoni, Wuchereria bancrofti*),

S. stercoralis also, given its capacity for chronic longstanding infection, can modulate responses to bystander antigens particularly in the context of infection with other pathogens such as *Mycobacterium tuberculosis* (George *et al.* 2015) and HTLV-1 (Mitre *et al.* 2003; Montes *et al.* 2009; Salles *et al.* 2013).

DIAGNOSIS

For the chronically infected, asymptomatic individual, diagnosis of strongyloidiasis can be challenging (Levenhagen and Costa-Cruz, 2014; Buonfrate *et al.* 2015; Toledo *et al.* 2015). Diagnosis of hyper-infection syndrome/disseminated *S. stercoralis* infection is much less difficult given the large numbers of larvae often seen in the stool or other bodily fluids including CSF, pleural fluid, bronchoalveolar lavage fluid.

Parasitological methods

Definitive diagnosis relies on detection of larvae in the stool. However, intermittent and scanty

excretion of larvae limits the utility of standard stool studies. Various investigators have attempted to improve the diagnostic yield of stool examination using techniques such as direct smear of feces in saline/Lugol's iodine stain, Baermann concentration, Harada-Mori filter paper culture, quantitative formalin ethyl acetate concentration technique and nutrient agar plate cultures [see (Sato *et al.* 1995)]. Sensitivity improved to 100% when seven stool samples were studied (Siddiqui and Berk, 2001). Duodenal aspiration, while more sensitive than stool examination, is an invasive procedure that makes it a less favourable option. Duodenal biopsy, when performed, can demonstrate parasites nested in the gastric crypts or duodenal glands, as well as eosinophil infiltration of the lamina propria (Rivasi *et al.* 2006).

Immunological methods

Antibody detection. A number of immunoassays, most notably enzyme-linked immunosorbent assays (ELISAs), have been increasingly used in conjunction with stool studies to increase diagnostic sensitivity. The high negative predictive value of these immunoassays can be particularly useful in excluding *S. stercoralis* infection as part of the differential diagnosis. Despite their utility, antibody-based immunoassays have several limitations including: (1) cross-reactivity in patients with active filarial infections; (2) lower sensitivity in patients with haematologic malignancies or HTLV-1 infection; and (3) the inability to distinguish between current and past infection. Moreover, the current available immunoassays [see (Levenhagen and Costa-Cruz, 2014; Buonfrate *et al.* 2015; Toledo *et al.* 2015) for a comprehensive discussion] relies on the preparation of *S. stercoralis* larval antigen from stool samples of heavily infected humans or experimentally infected animals or from related (but not *S. stercoralis*) *Strongyloides* species (e.g. *S. ratti*).

To overcome some of these drawbacks, *S. stercoralis*-specific recombinant antigens, such as NIE (Ravi *et al.* 2002) and SsIR (Ramachandran *et al.* 1998), were proposed as alternatives to the crude antigen-based immunoassays currently in use. Using a number of formats including ELISA [(Krolewiecki *et al.* 2010), luciferase immunoprecipitation systems (Ramanathan *et al.* 2008; Krolewiecki *et al.* 2010; Bisoffi *et al.* 2014)] and diffraction-based biosensors (Pak *et al.* 2014) the use of recombinant NIE and/or SsIR has improved greatly the diagnostic accuracy and utility of these antibody-based assays (Bisoffi *et al.* 2014; Levenhagen and Costa-Cruz, 2014; Buonfrate *et al.* 2015; Toledo *et al.* 2015).

Antigen detection. Coproantigen detection assays have the ability to overcome some of the limitations seen in immunoassays that measure antibody (see above). There have been several capture ELISA assays developed for *S. stercoralis* coproantigen detection (El-Badry, 2009; Sykes and McCarthy, 2011), and both of these assays have been performed on relatively few samples and are only available in a research setting.

Molecular diagnosis. Molecular diagnostics – using standard (and/or nested-) PCR, qPCR or loop-mediated isothermal amplification assays – have been increasingly gaining traction for use stool-based assays given their high degree of specificity and sensitivity (ten Hove *et al.* 2009; Verweij *et al.* 2009; Taniuchi *et al.* 2011; Mejia *et al.* 2013; Sultana *et al.* 2013; Watts *et al.* 2014; Easton *et al.* 2016; Llewellyn *et al.* 2016). Indeed, the improved specificity relies on the specific DNA targets used [18S rRNA, IST1, cytochrome *c* oxidase subunit 1 or the highly repetitive interspersed repeat sequence (Moore *et al.* 1996)] and the improved sensitivity has resulted from better methods for DNA extraction in stool (ten Hove *et al.* 2009; Taniuchi *et al.* 2011; Liu *et al.* 2013; Mejia *et al.* 2013; Sultana *et al.* 2013; Easton *et al.* 2016). These molecular diagnostic techniques likely identify active *S. stercoralis* infection as positivity has been shown to be lost following definitive treatment.

TREATMENT

The goals for therapy for *S. stercoralis* infection are to: (1) clear the organism completely thereby eliminating the possibility of autoinfection: (2) treat symptomatic infection; and (3) prevent complications associated with asymptomatic infection. Oral ivermectin ($200 \, \mu g \, kg^{-1}$ for 2 days) remains the treatment of choice for uncomplicated *S. stercoralis* infections (Keiser and Nutman, 2004; Suputtamongkol *et al.* 2011; Mejia and Nutman, 2012; Toledo *et al.* 2015; Henriquez-Camacho *et al.* 2016) as it targets both adults and larvae. Albendazole at 400 mg twice a day for 3–7 days has been shown to be slightly less effective than ivermectin for the treatment of uncomplicated *S. stercoralis* (Suputtamongkol *et al.* 2011; Henriquez-Camacho *et al.* 2016) and should be considered an alternative therapy. This is likely because albendazole primarily targets only the adult parasites. Thiabendazole ($25 \, mg \, kg^{-1} \, day^{-1}$) for three days can also be used, but because of gastrointestinal side effects, its use has been supplanted by ivermectin.

Hyperinfection syndrome should be considered a potential medical emergency. Thus, treatment should be started immediately if this diagnosis is being considered. Although no controlled trials have been performed in hyperinfection syndrome, daily ivermectin has been the *de facto* treatment with the length of treatment being for a minimum of 2 weeks (and often until there has been evidence of two full weeks of negative stool examination). Reduction of immunosuppressive therapy should also be an important part of treatment, but obviously needs to be weighed against long-term

outcomes of the underlying condition. There have been case reports of the improved efficacy of combination treatment with ivermectin and albendazole (Pornsuriyasak *et al.* 2004) but no randomized trials have been done.

Other methods of ivermectin administration may have to be used, particularly when patients are unable to take oral medication (even through a nasogastric tube) because of severe systemic illness or paralytic ileus. These include per rectal and parenteral formulations (Grein *et al.* 2010). The parenteral formulation is a veterinary formulation of ivermectin and should be reserved for extreme situations with no other options for clearing the *Strongyloides* infection (Marty *et al.* 2005; Salluh *et al.* 2005; Turner *et al.* 2005; Suputtamongkol *et al.* 2008; Lichtenberger *et al.* 2009; Marcos *et al.* 2011; Moura *et al.* 2012; Donadello *et al.* 2013; Barrett *et al.* 2016).

In conclusion, the gaps in our understanding of human strongyloidiasis, among the most neglected of the neglected tropical diseases (NTDs) (Olsen *et al.* 2009) are extraordinary given the rapid pace of scientific and clinical advances seen in related areas of parasitic and other tropical infectious diseases. Given its increasing importance as a significant public health problem (in high-, middle- and low-income countries) and the lack of a public health response (Krolewiecki *et al.* 2013), harnessing the insights made, to date, in our understanding of the basic biology and genetic makeup of *Strongyloides* (Hunt *et al.* 2016), the host response to this long-lived parasite (Breloer and Abraham, 2016), and molecularly based approaches to diagnosis and intervention must be made an imperative if we are to consider a world free of soil transmitted helminths (of which *S. stercoralis* is one of the most important).

REFERENCES

Al-Hasan, M. N., McCormick, M. and Ribes, J. A. (2007). Invasive enteric infections in hospitalized patients with underlying strongyloidiasis. *American Journal of Clinical Pathology* **128**, 622–627.

Anuradha, R., Munisankar, S., Bhootra, Y., Jagannathan, J., Dolla, C., Kumaran, P., Nutman, T. B. and Babu, S. (2016). IL-10- and TGFbeta-mediated Th9 Responses in a Human Helminth Infection. *PLoS Neglected Tropical Diseases* **10**, e0004317.

Anuradha, R., Munisankar, S., Bhootra, Y., Jagannathan, J., Dolla, C., Kumaran, P., Shen, K., Nutman, T. B. and Babu, S. (2015*a*). Systemic Cytokine profiles in *Strongyloides stercoralis* infection and alterations following treatment. *Infection and Immunity* **84**, 425–431.

Anuradha, R., Munisankar, S., Dolla, C., Kumaran, P., Nutman, T. B. and Babu, S. (2015*b*). Parasite antigen-specific regulation of Th1, Th2, and Th17 responses in *Strongyloides stercoralis* infection. *Journal of Immunology* **195**, 2241–2250.

Armignacco, O., Capecchi, A., De Mori, P. and Grillo, L. R. (1989). *Strongyloides stercoralis* hyperinfection and the acquired immunodeficiency syndrome. *American Journal of Medicine* **86**, 258.

Ashford, R. W., Barnish, G. and Viney, M. E. (1992). Strongyloides fuelleborni kellyi: infection and disease in Papua New Guinea. *Parasitology Today* **8**, 314–318.

Atkins, N. S., Lindo, J. F., Lee, M. G., Conway, D. J., Bailey, J. W., Robinson, R. D. and Bundy, D. A. (1997). Humoral responses in human strongyloidiasis: correlations with infection chronicity. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **91**, 609–613.

Atul, S., Ajay, D., Ritambhara, N., Harsh, M. and Ashish, B. (2005). An unusual cause of malabsorption in an immunocompetent host. *Journal of Ayub Medical College* **17**, 85–86.

Barrett, K. E., Neva, F. A., Gam, A. A., Cicmanec, J., London, W. T., Phillips, J. M. and Metcalfe, D. D. (1988). The immune response to nematode parasites: modulation of mast cell numbers and function during *Strongyloides stercoralis* infections in nonhuman primates. *American Journal of Tropical Medicine and Hygiene* **38**, 574–581.

Barrett, J., Broderick, C., Soulsby, H., Wade, P. and Newsholme, W. (2016). Subcutaneous ivermectin use in the treatment of severe *Strongyloides stercoralis* infection: two case reports and a discussion of the literature. *Journal of Antimicrobial Chemotherapy* **71**, 220–225.

Ben-Youssef, R., Baron, P., Edson, F., Raghavan, R. and Okechukwu, O. (2005). *Stronglyoides stercoralis* infection from pancreas allograft: case report. *Transplantation* **80**, 997–998.

Bisoffi, Z., Buonfrate, D., Sequi, M., Mejia, R., Cimino, R. O., Krolewiecki, A. J., Albonico, M., Gobbo, M., Bonafini, S., Angheben, A., Requena-Mendez, A., Munoz, J. and Nutman, T. B. (2014). Diagnostic accuracy of five serologic tests for *Strongyloides stercoralis* infection. *PLoS Neglected Tropical Diseases* **8**, e2640.

Breloer, M. and Abraham, D. (2016). *Strongyloides* infection in rodents: immune response and immune regulation. *Parasitology* 1–21 (in press).

Brown, M., Cartledge, J. D. and Miller, R. F. (2006). Dissemination of *Strongyloides stercoralis* as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. *International Journal of STD and AIDS* **17**, 560–561.

Buonfrate, D., Formenti, F., Perandin, F. and Bisoffi, Z. (2015). Novel approaches to the diagnosis of *Strongyloides stercoralis* infection. *Clinical Microbiology and Infection* **21**, 543–552.

Cahill, K. M. and Shevchuk, M. (1996). Fulminant, systemic strongyloidiasis in AIDS. *Annals of Tropical Medicine and Parasitology* **90**, 313–318.

Carvalho, E. M. and Da Fonseca Porto, A. (2004). Epidemiological and clinical interaction between HTLV-1 and *Strongyloides stercoralis*. *Parasite Immunology* **26**, 487–497.

Celedon, J. C., Mathur-Wagh, U., Fox, J., Garcia, R. and Wiest, P. M. (1994). Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. *Medicine* (*Baltimore*) **73**, 256–263.

Chaudhuri, B., Nanos, S., Soco, J. N. and McGrew, E. A. (1980). Disseminated *Strongyloides stercoralis* infestation detected by sputum cytology. *Acta Cytologica* **24**, 360–362.

Choi, S. W. and Reddy, P. (2014). Current and emerging strategies for the prevention of graft-versus-host disease. *Nature Reviews: Clinical Oncology* **11**, 536–547.

Chu, E., Whitlock, W. L. and Dietrich, R. A. (1990). Pulmonary hyperinfection syndrome with *Strongyloides stercoralis*. *Chest* **97**, 1475–1477.

Cirioni, O., Giacometti, A., Burzacchini, F., Balducci, M. and Scalise, G. (1996). *Strongyloides stercoralis* first-stage larvae in the lungs of a patient with AIDS: primary localization or a noninvasive form of dissemination? *Clinical Infectious Diseases* **22**, 737.

Crouch, P. R. and Shield, J. M. (1982). *Strongyloides* fulleborni-like infections in Anga children. *Papua New Guinea Medical Journal* **25**, 164–165.

Czachor, J. S. and Jonas, A. P. (2000). Transmission of *Strongyloides* steracolis person to person. *Journal of Travel Medicine* **7**, 211–212.

Dogan, C., Gayaf, M., Ozsoz, A., Sahin, B., Aksel, N., Karasu, I., Aydogdu, Z. and Turgay, N. (2014). Pulmonary *Strongyloides stercoralis* infection. *Respiratory Medicines Case Reports* **11**, 12–15.

Donadello, K., Cristallini, S., Taccone, F. S., Lorent, S., Vincent, J. L., de Backer, D. and Jacobs, F. (2013). *Strongyloides* disseminated infection successfully treated with parenteral ivermectin: case report with drug concentration measurements and review of the literature. *International Journal of Antimicrobial Agents* **42**, 580–583.

Dunlap, N. E., Shin, M. S., Polt, S. S. and Ho, K. J. (1984). Strongyloidiasis manifested as asthma. *Southern Medical Journal* **77**, 77–78.

Dutcher, J. P., Marcus, S. L., Tanowitz, H. B., Wittner, M., Fuks, J. Z. and Wiernik, P. H. (1990). Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma. *Cancer* **66**, 2417–2420.

Easton, A. V., Oliveira, R. G., O'Connell, E. M., Kepha, S., Mwandawiro, C. S., Njenga, S. M., Kihara, J. H., Mwatele, C., Odiere, M. R., Brooker, S. J., Webster, J. P., Anderson, R. M. and

Nutman, T. B. (2016). Multi-parallel qPCR provides increased sensitivity and diagnostic breadth for gastrointestinal parasites of humans: field-based inferences on the impact of mass deworming. *Parasites & Vectors* **9**, 38.

El-Badry, A. A. (2009). ELISA-based coproantigen in human strongyloidiaisis: a diagnostic method correlating with worm burden. *Journal of the Egyptian Society of Parasitology* **39**, 757–768.

Evans, A. C., Markus, M. B., Joubert, J. J. and Gunders, A. E. (1991). Bushman children infected with the nematode *Strongyloides fulleborni*. *South African Medical Journal* **80**, 410–411.

Freedman, D. O. (1991). Experimental infection of human subject with *Strongyloides* species. *Reviews of Infectious Diseases* **13**, 1221–1226.

Gatti, S., Lopes, R., Cevini, C., Ijaoba, B., Bruno, A., Bernuzzi, A. M., de Lio, P., Monco, A. and Scaglia, M. (2000). Intestinal parasitic infections in an institution for the mentally retarded. *Annals of Tropical Medicine and Parasitology* **94**, 453–460.

Genta, R. M. (1989). Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. *Reviews of Infectious Diseases* **11**, 755–767.

Genta, R. M. (1992). Dysregulation of strongyloidiasis: a new hypothesis. *Clinical Microbiology Reviews* **5**, 345–355.

Genta, R. M. and Lillibridge, J. P. (1989). Prominence of IgG4 antibodies in the human responses to *Strongyloides stercoralis* infection. *Journal of Infectious Diseases* **160**, 692–699.

Genta, R. M., Ottesen, E. A., Poindexter, R., Gam, A. A., Neva, F. A., Tanowitz, H. B. and Wittner, M. (1983). Specific allergic sensitization to *Strongyloides* antigens in human strongyloidiasis. *Laboratory Investigation* **48**, 633–638.

George, P. J., Anuradha, R., Kumar, N. P., Sridhar, R., Banurekha, V. V., Nutman, T. B. and Babu, S. (2014). Helminth infections coincident with active pulmonary tuberculosis inhibit mono- and multifunctional CD4$^+$ and CD8$^+$ T cell responses in a process dependent on IL-10. *PLoS Pathogens* **10**, e1004375.

George, P. J., Pavan Kumar, N., Jaganathan, J., Dolla, C., Kumaran, P., Nair, D., Banurekha, V. V., Shen, K., Nutman, T. B. and Babu, S. (2015). Modulation of pro- and anti-inflammatory cytokines in active and latent tuberculosis by coexistent *Strongyloides stercoralis* infection. *Tuberculosis (Edinb)* **95**, 822–828.

Ghosh, K. and Ghosh, K. (2007). *Strongyloides stercoralis* septicaemia following steroid therapy for eosinophilia: report of three cases. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **101**, 1163–1165.

Gompels, M. M., Todd, J., Peters, B. S., Main, J. and Pinching, A. J. (1991). Disseminated strongyloidiasis in AIDS: uncommon but important. *AIDS* **5**, 329–332.

Gordon, S. M., Gal, A. A., Solomon, A. R. and Bryan, J. A. (1994). Disseminated strongyloidiasis with cutaneous manifestations in an immunocompromised host. *Journal of the American Academy of Dermatology* **31**, 255–259.

Gotuzzo, E., Arango, C., de Queiroz-Campos, A. and Isturiz, R. E. (2000). Human T-cell lymphotropic virus-I in Latin America. *Infectious Disease Clinics of North America* **14**, 211–239, x-xi.

Grein, J. D., Mathisen, G. E., Donovan, S. and Fleckenstein, L. (2010). Serum ivermectin levels after enteral and subcutaneous administration for *Strongyloides* hyperinfection: a case report. *Scandinavian Journal of Infectious Diseases* **42**, 234–236.

Grove, D. I. (1989). *Strongyloidiasis: A Major Roundworm Infection of Man.* Taylor & Francis, Philadelphia, PA.

Grove, D. I. (1996). Human strongyloidiasis. *Advances in Parasitology* **38**, 251–309.

Guermani, A., Potenza, R., Isnardi, D., Peluso, M., Bosco, R. and Donadio, P. (2013). Organ donation and transplantation in migrants: Piedmont reality from 2004 to 2011. *Transplantation Proceedings* **45**, 2591–2593.

Gulbas, Z., Kebapci, M., Pasaoglu, O. and Vardareli, E. (2004). Successful ivermectin treatment of hepatic strongyloidiasis presenting with severe eosinophilia. *Southern Medical Journal* **97**, 907–910.

Harcourt-Webster, J. N., Scaravilli, F. and Darwish, A. H. (1991). *Strongyloides stercoralis* hyperinfection in an HIV positive patient. *Journal of Clinical Pathology* **44**, 346–348.

Harish, K., Sunilkumar, R., Varghese, T. and Feroze, M. (2005). Strongyloidiasis presenting as duodenal obstruction. *Tropical Gastroenterology* **26**, 201–202.

Henriquez-Camacho, C., Gotuzzo, E., Echevarria, J., White, A. C., Jr., Terashima, A., Samalvides, F., Perez-Molina, J. A. and Plana, M. N. (2016). Ivermectin versus albendazole or thiabendazole for *Strongyloides stercoralis* infection. *Cochrane Database of Systematic Reviews* **1**, CD007745.

Hira, P. R. and Patel, B. G. (1977). *Strongyloides* fulleborni infections in man in Zambia. *American Journal of Tropical Medicine and Hygiene* **26**, 640–643.

Ho, P. L., Luk, W. K., Chan, A. C. and Yuen, K. Y. (1997). Two cases of fatal strongyloidiasis in Hong Kong. *Pathology* **29**, 324–326.

Hsieh, Y. P., Wen, Y. K. and Chen, M. L. (2006). Minimal change nephrotic syndrome in association with strongyloidiasis. *Clinical Nephrology* **66**, 459–463.

Hunt, V. L., Tsai, I. J., Coghlan, A., Reid, A. J., Holroyd, N., Foth, B. J., Tracey, A., Cotton, J. A., Stanley, E. J., Beasley, H., Bennett, H. M., Brooks, K., Harsha, B., Kajitani, R., Kulkarni, A., Harbecke, D., Nagayasu, E., Nichol, S., Ogura, Y., Quail, M. A., Randle, N., Xia, D., Brattig, N. W., Soblik, H., Ribeiro, D. M., Sanchez-Flores, A., Hayashi, T., Itoh, T., Denver, D. R., Grant, W., Stoltzfus, J. D., Lok, J. B., Murayama, H., Wastling, J., Streit, A., Kikuchi, T., Viney, M. and Berriman, M. (2016). The genomic basis of parasitism in the *Strongyloides* clade of nematodes. *Nature Genetics* **48**, 299–307.

Husni, R. N., Gordon, S. M., Longworth, D. L. and Adal, K. A. (1996). Disseminated *Strongyloides stercoralis* infection in an immunocompetent patient. *Clinical Infectious Diseases* **23**, 663.

Iriemenam, N. C., Sanyaolu, A. O., Oyibo, W. A. and Fagbenro-Beyioku, A. F. (2010). *Strongyloides stercoralis* and the immune response. *Parasitology International* **59**, 9–14.

Jain, A. K., Agarwal, S. K. and el-Sadr, W. (1994). *Streptococcus bovis* bacteremia and meningitis associated with *Strongyloides stercoralis* colitis in a patient infected with human immunodeficiency virus. *Clinical Infectious Diseases* **18**, 253–254.

Jamil, S. A. and Hilton, E. (1992). The *Strongyloides* hyperinfection syndrome. *New York State Journal of Medicine* **92**, 67–68.

Keiser, P. B. and Nutman, T. B. (2004). *Strongyloides stercoralis* in the immunocompromised population. *Clinical Microbiology Reviews* **17**, 208–217.

Kennedy, S., Campbell, R. M., Lawrence, J. E., Nichol, G. M. and Rao, D. M. (1989). A case of severe *Strongyloides stercoralis* infection with jejunal perforation in an Australian ex-prisoner-of-war. *Medical Journal of Australia* **150**, 92–93.

Khieu, V., Schar, F., Forrer, A., Hattendorf, J., Marti, H., Duong, S., Vounatsou, P., Muth, S. and Odermatt, P. (2014). High prevalence and spatial distribution of *Strongyloides stercoralis* in rural Cambodia. *PLoS Neglected Tropical Diseases* **8**, e2854.

Kramer, M. R., Gregg, P. A., Goldstein, M., Llamas, R. and Krieger, B. P. (1990). Disseminated strongyloidiasis in AIDS and non-AIDS immunocompromised hosts: diagnosis by sputum and bronchoalveolar lavage. *Southern Medical Journal* **83**, 1226–1229.

Krolewiecki, A. J., Ramanathan, R., Fink, V., McAuliffe, I., Cajal, S. P., Won, K., Juarez, M., Di Paolo, A., Tapia, L., Acosta, N., Lee, R., Lammie, P., Abraham, D. and Nutman, T. B. (2010). Improved diagnosis of *Strongyloides stercoralis* using recombinant antigen-based serologies in a community-wide study in northern Argentina. *Clinical and Vaccine Immunology* **17**, 1624–1630.

Krolewiecki, A. J., Lammie, P., Jacobson, J., Gabrielli, A. F., Levecke, B., Socias, E., Arias, L. M., Sosa, N., Abraham, D., Cimino, R., Echazu, A., Crudo, F., Vercruysse, J. and Albonico, M. (2013). A public health response against *Strongyloides stercoralis*: time to look at soil-transmitted helminthiasis in full. *PLoS Neglected Tropical Diseases* **7**, e2165.

Lai, C. P., Hsu, Y. H., Wang, J. H. and Lin, C. M. (2002). *Strongyloides stercoralis* infection with bloody pericardial effusion in a non-immunosuppressed patient. *Circulation Journal* **66**, 613–614.

Leighton, P. M. and MacSween, H. M. (1990). *Strongyloides stercoralis*. The cause of an urticarial-like eruption of 65 years' duration. *Archives of Internal Medicine* **150**, 1747–1748.

Levenhagen, M. A. and Costa-Cruz, J. M. (2014). Update on immunologic and molecular diagnosis of human strongyloidiasis. *Acta Tropica* **135**, 33–43.

Levi, G. C., Kallas, E. G. and Ramos Moreira Leite, K. (1997). Disseminated *Strongyloides stercoralis* infection in an AIDS patient: the role of suppressive therapy. *Brazilian Journal of Infectious Diseases* **1**, 48–51.

Lichtenberger, P., Rosa-Cunha, I., Morris, M., Nishida, S., Akpinar, E., Gaitan, J., Tzakis, A. and Doblecki-Lewis, S. (2009). Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin. *Transplant Infectious Disease* **11**, 137–142.

Liepman, M. (1975). Disseminated *Strongyloides stercoralis*. A complication of immunosuppression. *JAMA* **231**, 387–388.

Link, K. and Orenstein, R. (1999). Bacterial complications of strongyloidiasis: *Streptococcus bovis* meningitis. *Southern Medical Journal* **92**, 728–731.

Liu, J., Gratz, J., Amour, C., Kibiki, G., Becker, S., Janaki, L., Verweij, J. J., Taniuchi, M., Sobuz, S. U., Haque, R., Haverstick, D. M. and Houpt, E. R. (2013). A laboratory-developed TaqMan Array Card for simultaneous detection of 19 enteropathogens. *Journal of Clinical Microbiology* **51**, 472–480.

Llewellyn, S., Inpankaew, T., Nery, S. V., Gray, D. J., Verweij, J. J., Clements, A. C., Gomes, S. J., Traub, R. and McCarthy, J. S. (2016). Application of a multiplex quantitative PCR to assess prevalence and intensity of intestinal parasite infections in a controlled clinical trial. *PLoS Neglected Tropical Diseases* **10**, e0004380.

Mansfield, L. S., Niamatali, S., Bhopale, V., Volk, S., Smith, G., Lok, J. B., Genta, R. M. and Schad, G. A. (1996). *Strongyloides stercoralis*: maintenance of exceedingly chronic infections. *American Journal of Tropical Medicine and Hygiene* **55**, 617–624.

Marcos, L. A., Terashima, A., Canales, M. and Gotuzzo, E. (2011). Update on strongyloidiasis in the immunocompromised host. *Current Infectious Disease Reports* **13**, 35–46.

Marty, F. M., Lowry, C. M., Rodriguez, M., Milner, D. A., Pieciak, W. S., Sinha, A., Fleckenstein, L. and Baden, L. R. (2005). Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. *Clinical Infectious Diseases* **41**, e5–e8.

Mascarello, M., Gobbi, F., Angheben, A., Gobbo, M., Gaiera, G., Pegoraro, M., Lanzafame, M., Buonfrate, D., Concia, E. and Bisoffi, Z. (2011). Prevalence of *Strongyloides stercoralis* infection among HIV-positive immigrants attending two Italian hospitals, from 2000 to 2009. *Annals of Tropical Medicine and Parasitology* **105**, 617–623.

McLarnon, M. and Ma, P. (1981). Brain stem glioma complicated by *Strongyloides stercoralis*. *Annals of Clinical and Laboratory Science* **11**, 546–549.

McNeely, D. J., Inouye, T., Tam, P. Y. and Ripley, S. D. (1980). Acute respiratory failure due to strongyloidiasis in polymyositis. *Journal of Rheumatology* **7**, 745–750.

McRury, J., De Messias, I. T., Walzer, P. D., Huitger, T. and Genta, R. M. (1986). Specific IgE responses in human strongyloidiasis. *Clinical and Experimental Immunology* **65**, 631–638.

Mejia, R. and Nutman, T. B. (2012). Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by *Strongyloides stercoralis*. *Current Opinion in Infectious Diseases* **25**, 458–463.

Mejia, R., Vicuna, Y., Broncano, N., Sandoval, C., Vaca, M., Chico, M., Cooper, P. J. and Nutman, T. B. (2013). A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. *American Journal of Tropical Medicine and Hygiene* **88**, 1041–1047.

Mitre, E., Thompson, R. W., Carvalho, E. M., Nutman, T. B. and Neva, F. A. (2003). Majority of interferon-gamma-producing CD4$^+$ cells in patients infected with human T cell lymphotrophic virus do not express tax protein. *Journal of Infectious Diseases* **188**, 428–432.

Mokaddas, E. M., Shati, S., Abdulla, A., Nampoori, N. R., Iqbal, J., Nair, P. M., Said, T., Abdulhalim, M. and Hira, P. R. (2009). Fatal strongyloidiasis in three kidney recipients in Kuwait. *Medical Principles and Practice* **18**, 414–417.

Montes, M., Sanchez, C., Verdonck, K., Lake, J. E., Gonzalez, E., Lopez, G., Terashima, A., Nolan, T., Lewis, D. E., Gotuzzo, E. and White, A. C., Jr. (2009). Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to *Strongyloides stercoralis* antigen. *PLoS Neglected Tropical Diseases* **3**, e456.

Moore, T. A., Ramachandran, S., Gam, A. A., Neva, F. A., Lu, W., Saunders, L., Williams, S. A. and Nutman, T. B. (1996). Identification of novel sequences and codon usage in *Strongyloides stercoralis*. *Molecular and Biochemical Parasitology* **79**, 243–248.

Mori, S., Konishi, T., Matsuoka, K., Deguchi, M., Ohta, M., Mizuno, O., Ueno, T., Okinaka, T., Nishimura, Y., Ito, N. and Nakano, T. (1998). Strongyloidiasis associated with nephrotic syndrome. *Internal Medicine* **37**, 606–610.

Moura, E. B., Maia Mde, O., Ghazi, M., Amorim, F. F. and Pinhati, H. M. (2012). Salvage treatment of disseminated strongyloidiasis in an immunocompromised patient: therapy success with subcutaneous ivermectin. *Brazilian Journal of Infectious Diseases* **16**, 479–481.

Neefe, L. I., Pinilla, O., Garagusi, V. F. and Bauer, H. (1973). Disseminated strongyloidiasis with cerebral involvement. A complication of corticosteroid therapy. *American Journal of Medicine* **55**, 832–838.

Neva, F. A. (1986). Biology and immunology of human strongyloidiasis. *Journal of Infectious Diseases* **153**, 397–406.

Neva, F. A., Filho, J. O., Gam, A. A., Thompson, R., Freitas, V., Melo, A. and Carvalho, E. M. (1998). Interferon-gamma and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and *Strongyloides stercoralis*. *Journal of Infectious Diseases* **178**, 1856–1859.

Newton, R. C., Limpuangthip, P., Greenberg, S., Gam, A. and Neva, F. A. (1992). *Strongyloides stercoralis* hyperinfection in a carrier of HTLV-I virus with evidence of selective immunosuppression. *American Journal of Medicine* **92**, 202–208.

Nomura, J. and Rekrut, K. (1996). *Strongyloides stercoralis* hyperinfection syndrome in a patient with AIDS: diagnosis by fluorescent microscopy. *Clinical Infectious Diseases* **22**, 736.

O'Connell, E. M. and Nutman, T. B. (2015). Eosinophilia in infectious diseases. *Immunology and Allergy Clinics of North America* **35**, 493–522.

Olsen, A., van Lieshout, L., Marti, H., Polderman, T., Polman, K., Steinmann, P., Stothard, R., Thybo, S., Verweij, J. J. and Magnussen, P. (2009). Strongyloidiasis – the most neglected of the neglected tropical diseases? *Transactions of the Royal Society of Tropical Medicine and Hygiene* **103**, 967–972.

Pak, B. J., Vasquez-Camargo, F., Kalinichenko, E., Chiodini, P. L., Nutman, T. B., Tanowitz, H. B., McAuliffe, I., Wilkins, P., Smith, P. T., Ward, B. J., Libman, M. D. and Ndao, M. (2014). Development of a rapid serological assay for the diagnosis of strongyloidiasis using a novel diffraction-based biosensor technology. *PLoS Neglected Tropical Diseases* **8**, e3002.

Pampiglione, S. and Ricciardi, M. L. (1971). The presence of *Strongyloides* fulleborni von Linstow, 1905, in man in Central and East Africa. *Parassitologia* **13**, 257–269.

Patel, G., Arvelakis, A., Sauter, B. V., Gondolesi, G. E., Caplivski, D. and Huprikar, S. (2008). *Strongyloides* hyperinfection syndrome after intestinal transplantation. *Transplant Infectious Disease* **10**, 137–141.

Pelletier, L. L., Jr. (1984). Chronic strongyloidiasis in World War II Far East ex-prisoners of war. *American Journal of Tropical Medicine and Hygiene* **33**, 55–61.

Pelletier, L. L., Jr. and Gabre-Kidan, T. (1985). Chronic strongyloidiasis in Vietnam veterans. *American Journal of Medicine* **78**, 139–140.

Pornsuriyasak, P., Niticharoenpong, K. and Sakapibunnan, A. (2004). Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. *Southeast Asian Journal of Tropical Medicine and Public Health* **35**, 531–534.

Porto, A. F., Neva, F. A., Bittencourt, H., Lisboa, W., Thompson, R., Alcantara, L. and Carvalho, E. M. (2001). HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. *Parasite Immunology* **23**, 503–507.

Posey, D. L., Blackburn, B. G., Weinberg, M., Flagg, E. W., Ortega, L., Wilson, M., Secor, W. E., Sanders-Lewis, K., Won, K. and Maguire, J. H. (2007). High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. *Clinical Infectious Diseases* **45**, 1310–1315.

Ramachandran, S., Thompson, R. W., Gam, A. A. and Neva, F. A. (1998). Recombinant cDNA clones for immunodiagnosis of strongyloidiasis. *Journal of Infectious Diseases* **177**, 196–203.

Ramanathan, R., Burbelo, P. D., Groot, S., Iadarola, M. J., Neva, F. A. and Nutman, T. B. (2008). A luciferase immunoprecipitation systems assay enhances the sensitivity and specificity of diagnosis of *Strongyloides stercoralis* infection. *Journal of Infectious Diseases* **198**, 444–451.

Ramanathan, R., Varma, S., Ribeiro, J. M., Myers, T. G., Nolan, T. J., Abraham, D., Lok, J. B. and Nutman, T. B. (2011). Microarray-based analysis of differential gene expression between infective and noninfective larvae of *Strongyloides stercoralis*. *PLoS Neglected Tropical Diseases* **5**, e1039.

Ravi, V., Ramachandran, S., Thompson, R. W., Andersen, J. F. and Neva, F. A. (2002). Characterization of a recombinant immunodiagnostic antigen (NIE) from *Strongyloides stercoralis* L3-stage larvae. *Molecular and Biochemical Parasitology* **125**, 73–81.

Richter, J., Muller-Stover, I., Strothmeyer, H., Gobels, K., Schmitt, M. and Haussinger, D. (2006). Arthritis associated with *Strongyloides stercoralis* infection in HLA B-27-positive African. *Parasitology Research* **99**, 706–707.

Rivasi, F., Pampiglione, S., Boldorini, R. and Cardinale, L. (2006). Histopathology of gastric and duodenal *Strongyloides stercoralis* locations in fifteen immunocompromised subjects. *Archives of Pathology and Laboratory Medicine* **130**, 1792–1798.

Robson, D., Welch, E., Beeching, N. J. and Gill, G. V. (2009). Consequences of captivity: health effects of far East imprisonment in World War II. *QJM* **102**, 87–96.

Rodrigues, R. M., de Oliveira, M. C., Sopelete, M. C., Silva, D. A., Campos, D. M., Taketomi, E. A. and Costa-Cruz, J. M. (2007). IgG1, IgG4, and IgE antibody responses in human strongyloidiasis by ELISA using *Strongyloides ratti* saline extract as heterologous antigen. *Parasitology Research* **101**, 1209–1214.

Ronan, S. G., Reddy, R. L., Manaligod, J. R., Alexander, J. and Fu, T. (1989). Disseminated strongyloidiasis presenting as purpura. *Journal of the American Academy of Dermatology* **21**, 1123–1125.

Rossi, C. L., Takahashi, E. E., Partel, C. D., Teodoro, L. G. and da Silva, L. J. (1993). Total serum IgE and parasite-specific IgG and IgA

antibodies in human strongyloidiasis. *Revista do Instituto de Medicina Tropical de São Paulo* **35**, 361–365.

Said, T., Nampoory, M. R., Nair, M. P., Halim, M. A., Shetty, S. A., Kumar, A. V., Mokadas, E., Elsayed, A., Johny, K. V., Samhan, M. and Al-Mousawi, M. (2007). Hyperinfection strongyloidiasis: an anticipated outbreak in kidney transplant recipients in Kuwait. *Transplantation Proceedings* **39**, 1014–1015.

Salles, F., Bacellar, A., Amorim, M., Orge, G., Sundberg, M., Lima, M., Santos, S., Porto, A. and Carvalho, E. (2013). Treatment of strongyloidiasis in HTLV-1 and *Strongyloides stercoralis* coinfected patients is associated with increased TNFalpha and decreased soluble IL2 receptor levels. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **107**, 526–529.

Salluh, J. I., Feres, G. A., Velasco, E., Holanda, G. S., Toscano, L. and Soares, M. (2005). Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated strongyloidiasis and septic shock. *Intensive Care Medicine* **31**, 1292.

Santos, S. B., Porto, A. F., Muniz, A. L., Jesus, A. R. and Carvalho, E. M. (2004). Clinical and immunological consequences of human T cell leukemia virus type-I and *Schistosoma mansoni* co-infection. *Memorias do Instituto Oswaldo Cruz* **99**, 121–126.

Sato, Y., Kobayashi, J., Toma, H. and Shiroma, Y. (1995). Efficacy of stool examination for detection of *Strongyloides* infection. *American Journal of Tropical Medicine and Hygiene* **53**, 248–250.

Schad, G. A., Aikens, L. M. and Smith, G. (1989). *Strongyloides stercoralis*: is there a canonical migratory route through the host? *Journal of Parasitology* **75**, 740–749.

Schar, F., Trostdorf, U., Giardina, F., Khieu, V., Muth, S., Marti, H., Vounatsou, P. and Odermatt, P. (2013). *Strongyloides stercoralis*: Global Distribution and Risk Factors. *PLoS Neglected Tropical Diseases* **7**, e2288.

Schar, F., Inpankaew, T., Traub, R. J., Khieu, V., Dalsgaard, A., Chimnoi, W., Chhoun, C., Sok, D., Marti, H., Muth, S. and Odermatt, P. (2014). The prevalence and diversity of intestinal parasitic infections in humans and domestic animals in a rural Cambodian village. *Parasitology International* **63**, 597–603.

Schar, F., Giardina, F., Khieu, V., Muth, S., Vounatsou, P., Marti, H. and Odermatt, P. (2016). Occurrence of and risk factors for *Strongyloides stercoralis* infection in South-East Asia. *Acta Tropica* doi: 10.1016/j.actatropica.2015.03.008 (in press).

Scowden, E. B., Schaffner, W. and Stone, W. J. (1978). Overwhelming strongyloidiasis: an unappreciated opportunistic infection. *Medicine (Baltimore)* **57**, 527–544.

Seet, R. C., Lau, L. G. and Tambyah, P. A. (2005). *Strongyloides* hyperinfection and hypogammaglobulinemia. *Clinical and Diagnostic Laboratory Immunology* **12**, 680–682.

Siddiqui, A. A. and Berk, S. L. (2001). Diagnosis of *Strongyloides stercoralis* infection. *Clinical Infectious Diseases* **33**, 1040–1047.

Stewart, D. M., Ramanathan, R., Mahanty, S., Fedorko, D. P., Janik, J. E. and Morris, J. C. (2011). Disseminated *Strongyloides stercoralis* infection in HTLV-1-associated adult T-cell leukemia/lymphoma. *Acta Haematologica* **126**, 63–67.

Stone, W. J. and Schaffner, W. (1990). *Strongyloides* infections in transplant recipients. *Seminars in Respiratory Infections* **5**, 58–64.

Sugiyama, K., Hasegawa, Y., Nagasawa, T. and Hitomi, S. (2006). Exposure of medical staff to *Strongyloides stercolaris* from a patient with disseminated strongyloidiasis. *Journal of Infection and Chemotherapy* **12**, 217–219.

Sultana, Y., Jeoffreys, N., Watts, M. R., Gilbert, G. L. and Lee, R. (2013). Real-time polymerase chain reaction for detection of *Strongyloides stercoralis* in stool. *American Journal of Tropical Medicine and Hygiene* **88**, 1048–1051.

Suputtamongkol, Y., Kungpanichkul, N., Silpasakorn, S. and Beeching, N. J. (2008). Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis. *International Journal of Antimicrobial Agents* **31**, 46–49.

Suputtamongkol, Y., Premasathian, N., Bhumimuang, K., Waywa, D., Nilganuwong, S., Karuphong, E., Anekthananon, T., Wanachiwanawin, D. and Silpasakorn, S. (2011). Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. *PLoS Neglected Tropical Diseases* **5**, e1044.

Suvarna, D., Mehta, R., Sadasivan, S., Raj, V. V. and Balakrishnan, V. (2005). Infiltrating *Strongyloides stercoralis* presenting as duodenal obstruction. *Indian Journal of Gastroenterology* **24**, 173–174.

Sykes, A. M. and McCarthy, J. S. (2011). A coproantigen diagnostic test for *Strongyloides* infection. *PLoS Neglected Tropical Diseases* **5**, e955.

Takayanagui, O. M., Lofrano, M. M., Araugo, M. B. and Chimelli, L. (1995). Detection of *Strongyloides stercoralis* in the cerebrospinal fluid of a patient with acquired immunodeficiency syndrome. *Neurology* **45**, 193–194.

Taniuchi, M., Verweij, J. J., Noor, Z., Sobuz, S. U., Lieshout, L., Petri, W. A., Jr., Haque, R. and Houpt, E. R. (2011). High throughput multiplex PCR and probe-based detection with Luminex beads for seven intestinal parasites. *American Journal of Tropical Medicine and Hygiene* **84**, 332–337.

ten Hove, R. J., van Esbroeck, M., Vervoort, T., van den Ende, J., van Lieshout, L. and Verweij, J. J. (2009). Molecular diagnostics of intestinal parasites in returning travellers. *European Journal of Clinical Microbiology and Infectious Diseases* **28**, 1045–1053.

Thomas, M. C. and Costello, S. A. (1998). Disseminated strongyloidiasis arising from a single dose of dexamethasone before stereotactic radiosurgery. *International Journal of Clinical Practice* **52**, 520–521.

Thompson, J. R. and Berger, R. (1991). Fatal adult respiratory distress syndrome following successful treatment of pulmonary strongyloidiasis. *Chest* **99**, 772–774.

Tiwari, S., Rautaraya, B. and Tripathy, K. P. (2012). Hyperinfection of *Strongyloides stercoralis* in an immunocompetent patient. *Tropical Parasitology* **2**, 135–137.

Toledo, R., Munoz-Antoli, C. and Esteban, J. G. (2015). Strongyloidiasis with emphasis on human infections and its different clinical forms. *Advances in Parasitology* **88**, 165–241.

Tullis, D. C. (1970). Bronchial asthma associated with intestinal parasites. *New England Journal of Medicine* **282**, 370–372.

Turner, S. A., Maclean, J. D., Fleckenstein, L. and Greenaway, C. (2005). Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. *American Journal of Tropical Medicine and Hygiene* **73**, 911–914.

Verweij, J. J., Canales, M., Polman, K., Ziem, J., Brienen, E. A., Polderman, A. M. and van Lieshout, L. (2009). Molecular diagnosis of *Strongyloides stercoralis* in faecal samples using real-time PCR. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **103**, 342–346.

Vince, J. D., Ashford, R. W., Gratten, M. J. and Bana-Koiri, J. (1979). *Strongyloides* species infestation in young infants of papu, New Guinea: association with generalized oedema. *Papua New Guinea Medical Journal* **22**, 120–127.

Viney, M. E. and Lok, J. B. (2007). *Strongyloides* spp. *WormBook: The Online Review of C. Elegans Biology* 1–15. doi: 10.1895/wormbook.1.141.1 http://www.wormbook.org.

Vishwanath, S., Baker, R. A. and Mansheim, B. J. (1982). *Strongyloides* infection and meningitis in an immunocompromised host. *American Journal of Tropical Medicine and Hygiene* **31**, 857–858.

Walson, J. L., Stewart, B. T., Sangare, L., Mbogo, L. W., Otieno, P. A., Piper, B. K., Richardson, B. A. and John-Stewart, G. (2010). Prevalence and correlates of helminth co-infection in Kenyan HIV-1 infected adults. *PLoS Neglected Tropical Diseases* **4**, e644.

Watts, M. R., James, G., Sultana, Y., Ginn, A. N., Outhred, A. C., Kong, F., Verweij, J. J., Iredell, J. R., Chen, S. C. and Lee, R. (2014). A loop-mediated isothermal amplification (LAMP) assay for *Strongyloides stercoralis* in stool that uses a visual detection method with SYTO-82 fluorescent dye. *American Journal of Tropical Medicine and Hygiene* **90**, 306–311.

Weiser, J. A., Scully, B. E., Bulman, W. A., Husain, S. and Grossman, M. E. (2011). Periumbilical parasitic thumbprint purpura: *Strongyloides* hyperinfection syndrome acquired from a cadaveric renal transplant. *Transplant Infectious Disease* **13**, 58–62.

Wirk, B. and Wingard, J. R. (2009). *Strongyloides stercoralis* hyperinfection in hematopoietic stem cell transplantation. *Transplant Infectious Disease* **11**, 143–148.

Wolfe, R. A., Roys, E. C. and Merion, R. M. (2010). Trends in organ donation and transplantation in the United States, 1999–2008. *American Journal of Transplantation* **10**, 961–972.

Wurtz, R., Mirot, M., Fronda, G., Peters, C. and Kocka, F. (1994). Short report: gastric infection by *Strongyloides stercoralis*. *American Journal of Tropical Medicine and Hygiene* **51**, 339–340.

Yassin, M. A., El Omri, H., Al-Hijji, I., Taha, R., Hassan, R., Aboudi, K. A. and El-Ayoubi, H. (2010). Fatal *Strongyloides stercoralis* hyper-infection in a patient with multiple myeloma. *Brazilian Journal of Infectious Diseases* **14**, 536–539.

Yee, A., Boylen, C. T., Noguchi, T., Klatt, E. C. and Sharma, O. P. (1987). Fatal *Strongyloides stercoralis* infection in a patient receiving corticosteroids. *Western Journal of Medicine* **146**, 363–364.

Yoeli, M., Most, H., Hammond, J. and Scheinesson, G. P. (1972). Parasitic infections in a closed community. Results of a 10-year survey in Willowbrook State School. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **66**, 764–776.

Yoshida, H., Endo, H., Tanaka, S., Ishikawa, A., Kondo, H. and Nakamura, T. (2006). Recurrent paralytic ileus associated with strongyloidiasis in a patient with systemic lupus erythematosus. *Modern Rheumatology* **16**, 44–47.